C07D 265/22
Oxygen atoms
C07D265/22 (Oxygen atoms) appears on 138 US grants and 82 published applications in this corpus.
Search patents in C07D- Granted patents
- 138
- Published applications
- 82
- Assignees
- 82
- Inventors
- 344
- Latest grant
- 2 Apr 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 3 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 0 | 0 |
| 1981 | 2 | 0 |
| 1982 | 3 | 0 |
| 1983 | 2 | 0 |
| 1984 | 2 | 0 |
| 1985 | 6 | 0 |
| 1986 | 3 | 0 |
| 1987 | 4 | 0 |
| 1988 | 5 | 0 |
| 1989 | 4 | 0 |
| 1990 | 2 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 4 | 0 |
| 1997 | 4 | 0 |
| 1998 | 6 | 0 |
| 1999 | 1 | 0 |
| 2000 | 7 | 0 |
| 2001 | 3 | 1 |
| 2002 | 1 | 4 |
| 2003 | 4 | 4 |
| 2004 | 1 | 7 |
| 2005 | 4 | 1 |
| 2006 | 1 | 6 |
| 2007 | 4 | 3 |
| 2008 | 0 | 1 |
| 2009 | 3 | 4 |
| 2010 | 6 | 2 |
| 2011 | 1 | 7 |
| 2012 | 4 | 3 |
| 2013 | 0 | 3 |
| 2014 | 3 | 1 |
| 2015 | 3 | 4 |
| 2016 | 2 | 4 |
| 2017 | 6 | 4 |
| 2018 | 6 | 8 |
| 2019 | 4 | 3 |
| 2020 | 2 | 3 |
| 2021 | 5 | 3 |
| 2022 | 1 | 1 |
| 2023 | 0 | 0 |
| 2024 | 1 | 3 |
| 2025 | 0 | 2 |
By publication year. Applications have been published since 2001.
Recent patents
- Substituted imidazoles for preventing and/or treating cell or tissue necrosis2 Apr 2024US 11,945,787 B2Ela Pharma Ltd.
- Substituted dihydrobenzoxazinones, dihydroquinolones, and methods of their use and synthesis13 Sep 2022US 11,440,892 B2Northwestern University
- Histone acetyltransferase activators and uses thereof7 Dec 2021US 11,191,768 B2The Trustees of Columbia University in the City of New York
- Process for the preparation of Deferasirox3 Aug 2021US 11,078,167 B2Aurobindo Pharma Ltd
- Substituted thiazoles for preventing and/or treating cell or tissue necrosis6 Apr 2021US 10,968,185 B2Ela Pharma Ltd.
- Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto11 Sep 2025US 2025/0282740 A1Ela Pharma Ltd.
- 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof15 May 2025US 2025/0154107 A1BeiGene Switzerland GmbH
- Flavonoid derivatives with gabaa receptor activity and methods of use5 Dec 2024US 2024/0398821 A1Rutgers, The State University of New Jersey
- Compositions for treating and/or preventing cell or tissue necrosis specifically targeting cathepsin c and/or cela1 and/or cela3a and/or structurally related enzymes thereto5 Sep 2024US 2024/0294480 A1Ela Pharma Ltd.
- Small Molecule Inhibitors of PBRM1-BD213 Jun 2024US 2024/0190828 A1The Medical College of Wisconsin, Inc.
Most cited
By later US patents
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase226US 5,480,883 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1996
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase209US 5,409,930 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1995
- Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase198US 5,710,158 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998
- Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase171US 5,646,153 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1997
- Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties144US 5,721,237 ARhone-Poulenc Rorer Pharmaceuticals Inc. · 1998